{"id":"artemether-lumefantrine-combination-plus-albendazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL4297927","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Artemether is a fast-acting artemisinin derivative that rapidly reduces parasite biomass by generating reactive oxygen species within infected red blood cells. Lumefantrine provides sustained antimalarial activity by inhibiting parasite heme polymerization. Albendazole is a broad-spectrum anthelmintic that disrupts microtubule formation in helminths, addressing the common co-infection of malaria and intestinal worms in endemic populations.","oneSentence":"This combination kills malaria parasites through artemether's rapid parasite clearance and lumefantrine's sustained blood schizonticide activity, while albendazole eliminates co-occurring helminth infections.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:42:33.514Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Uncomplicated malaria (Plasmodium falciparum) with concurrent helminth infection"},{"name":"Malaria and soil-transmitted helminth co-infections in endemic regions"}]},"trialDetails":[{"nctId":"NCT01459146","phase":"PHASE4","title":"Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana","status":"UNKNOWN","sponsor":"Navrongo Health Research Centre, Ghana","startDate":"2010-12","conditions":"Malaria, Schistosomiasis, Helminthiasis","enrollment":345}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Artemether-lumefantrine combination plus albendazole","genericName":"Artemether-lumefantrine combination plus albendazole","companyName":"Navrongo Health Research Centre, Ghana","companyId":"navrongo-health-research-centre-ghana","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination kills malaria parasites through artemether's rapid parasite clearance and lumefantrine's sustained blood schizonticide activity, while albendazole eliminates co-occurring helminth infections. Used for Uncomplicated malaria (Plasmodium falciparum) with concurrent helminth infection, Malaria and soil-transmitted helminth co-infections in endemic regions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}